| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
7 companies
Karen P Robards last filed a Form 4 in April 2021, as Director at ATRC. The filings on record cover 7 companies. Karen P Robards's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 318,328 shares of ATRC. The ATRC filings lean toward selling, a net 5,800 shares.
Karen P Robards has 173 Form 4 filings on record from January 2015 to April 2021, across 16 companies: Director at Blackrock Muniyield Quality Fund (MQY), 2021; Director at BlackRock Technology & Private Equity Term Trust (BTX), 2021; Director at BlackRock Enhanced Large Cap Core Fund (CII), 2019–2020, and 13 more.
The 177 reported transactions were 162 option or other derivative awards, 5 open-market purchases, 4 option exercises and 2 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 5 purchases worth about $31K and 2 sales worth about $120K.
The largest open-market purchase was 4,000 shares of DSU at an average $3.48 on November 11, 2016, about $14K.
The largest open-market sale was 3,150 shares of ATRC at an average $19.53 on March 13, 2015, about $62K.
Shares as reported in the last Form 4 for each company; the most recent is from April 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2021 | BTX Blackrock Technology & Private Equity Term Trust | Director | Buy | 1 | $20.05 | $20.05 | New | +2.0% | -39.5% | |
| Feb 18, 2020 | BMEZ Blackrock Health Sciences Term Trust | Director | Buy | 50 | $21.30 | $1,064.85 | New | - | - | |
| Jun 26, 2019 | BSTZ Blackrock Science & Technology Term Trust | Director | Buy | 250 | $20.02 | $5,004.20 | New | - | - | |
| Jun 20, 2017 | BKT Blackrock Income Trust, Inc. | Director | Buy | 1,750 | $6.33 | $11,077.50 | New | - | - | |
| Nov 11, 2016 | DSU Blackrock Debt Strategies Fund, Inc. | Director | Buy | 4,000 | $3.48 | $13,907.60 | New | - | - | |
| May 6, 2015 | ATRC Atricure, Inc. | Director | Sale+OE | 2,650 | $22.18 | $58,777.00 | -0.9% | - | - | |
| Mar 13, 2015 | ATRC Atricure, Inc. | Director | Sale+OE | 3,150 | $19.53 | $61,519.50 | -1.1% | - | - |